Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

Completed · Phase 3

Conditions studied: Epilepsy

In brief

Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.

Key facts

Study ID

NCT00264615

Run by

GlaxoSmithKline

People needed

45

Starts

2005-10-01

Expected to finish

2006-06-01

Last updated by the study team

2016-09-23

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confident diagnosis of epilepsy.
• Currently on LAMICTAL and up to 2 concomitant AEDs (anti-epileptic drugs).

You may not qualify if…

• Females of childbearing potential cannot be on hormonal contraceptives or hormone replacement therapy.

Where it is running

• GSK Investigational Site — Anniston, Alabama, United States
• GSK Investigational Site — Sun City, Arizona, United States
• GSK Investigational Site — Lexington, Kentucky, United States
• GSK Investigational Site — Lexington, Kentucky, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Reno, Nevada, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Toledo, Ohio, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Nashville, Tennessee, United States
• GSK Investigational Site — Dallas, Texas, United States
• GSK Investigational Site — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.